NCT03450863

Study on How Fiasp® Can Influence Blood Sugar Levels of type1 Diabetic Patients in Their Daily Lives, With the Help of the Freestyle Libre® Device

Impact of Fiasp® on Glycaemic Control in a Real World Population With Type 1 Diabetes Mellitus Using Flash Glucose Monitoring

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 320 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to collect information about Fiasp® to evaluate how effective Fiasp® is in treating elevated blood sugar in patients with type 1 diabetes, compared with the participant's previous insulin treatment. The study will also assess how satisfied the participants are with the treatment with Fiasp® and the impact of the treatment on quality of life. The study has also been set up to learn more about how effective Fiasp® is in controlling the glucose levels during the day and night. The duration of the study is expected to be approximately 2 years. The participation is expected to be approximately 6-8 months for each patient.

Conditions

• Diabetes
• Diabetes Mellitus, Type 1 Diabetes

Interventions

Type	Name	Description
DRUG	Fast-acting insulin aspart	Patients will be treated with commercially available fast-acting insulin aspart as bolus insulin (multiple daily injection \[MDI\]) or as insulin used in the insulin pumps (continuous subcutaneous insulin infusion \[CSII\]). Dosing of fast-acting insulin aspart is individual and determined by the treating physician in accordance with the needs of the patient.

Timeline

• Start date: 2018-03-22
• Primary completion: 2019-09-04
• Completion: 2019-09-04
• First posted: 2018-03-01
• Last updated: 2020-03-18

Locations

1 site across 1 country: Germany